...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: What if
8
Mar 06, 2019 09:46AM
5
Mar 06, 2019 10:06AM
3
Mar 06, 2019 10:14AM
1
Mar 06, 2019 10:38AM
5
Mar 06, 2019 10:44AM
6
Mar 06, 2019 11:13AM
3
Mar 06, 2019 11:21AM
1
Mar 06, 2019 11:54AM
5
bfw
Mar 06, 2019 01:05PM
4
Mar 06, 2019 01:41PM
2
Mar 06, 2019 02:31PM
3
Mar 06, 2019 03:23PM
2
Mar 06, 2019 03:47PM
2
Mar 06, 2019 04:44PM
2
Mar 06, 2019 05:07PM
4
Mar 06, 2019 06:44PM
1
Mar 06, 2019 07:04PM
3
Mar 06, 2019 08:05PM
2
Mar 06, 2019 08:25PM
2
Mar 07, 2019 06:26AM
3
Mar 07, 2019 08:57AM
4
Mar 07, 2019 09:21AM
5
Mar 07, 2019 09:24AM
2
Mar 07, 2019 09:24AM
4
Mar 07, 2019 09:33AM
4
Mar 07, 2019 09:36AM
4
Mar 07, 2019 09:45AM
3
Mar 07, 2019 09:59AM

In retrospect IMO one of the biggest mistakes RVX management has ever made was, in ASSURE, not making the differentiation between rosuvastatin + 208 and atorvastatin + 208 a prespecified end point. To me heads should have rolled after that one.

I don't think ASSURE wasn't sufficiently powered to do that analysis.  And they would have needed some a priori hypothesis and prior evidence to justify that subgroup analysis. 

 

5
Mar 07, 2019 11:34AM
3
Mar 07, 2019 11:49AM
2
Mar 08, 2019 10:18AM
4
Mar 08, 2019 11:05AM
4
Mar 08, 2019 11:17AM
4
Mar 08, 2019 11:59AM
4
Mar 08, 2019 12:40PM
3
Mar 08, 2019 01:36PM
2
Mar 08, 2019 01:44PM
1
Mar 08, 2019 02:01PM
4
Mar 08, 2019 02:28PM
Share
New Message
Please login to post a reply